Full-Time

Senior Director

Regulatory Strategy, Povetacicept

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$232k - $348k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA + 1 more

More locations: Washington, DC, USA

Hybrid-Eligible: work remotely up to two days per week; or work five days per week on-site with ad hoc flexibility.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Data Analysis
Requirements
  • Bachelor's degree in Biology, Chemistry, or other related discipline
  • Typically requires 12 years of relevant pharmaceutical or biotech industry experience within regulatory affairs
  • 5 years of supervisory/management experience, or the equivalent combination of education and experience
  • Demonstrated technical expertise in regulatory affairs science including advanced knowledge of regulatory frameworks and external environments
  • Expert knowledge of global/regional/local regulatory legislation, laws, procedure and guidance for pharmaceutical development of medicines for human use
  • Advanced proficiency in analyzing and interpreting data, protocols, safety reporting, labeling and other activities related to the phases of drug development for assigned products.
Responsibilities
  • Leads and oversees the development of regulatory strategy for projects in phase 2 and 3 development including for regulatory submission documents and Health Authority communications
  • Represents GRA on core development teams, project teams, and collaborate with regional leaders and teams to ensure unified regulatory input into clinical programs and commercial strategy
  • Addresses complex issues, providing advanced regulatory solutions and guidance to cross-functional teams and align communication to and from cross-functional teams and GRA leadership
  • Counsels and advises senior management on status of global Regulatory Affairs strategies and tactics, procedures and practices
  • Leads the development and management of project plans and timelines and assigns and manages resources effectively to ensure all projects are appropriately prioritized and key goals are met on time
  • Works to influence regulatory environment through active participation in conferences and industry/agency regulatory meeting, committees and trade associations
  • Leads continuous improvement efforts on existing department processes and strategies, providing recommendations in area of expertise
  • Leads a small GRA functional team including participating in the skill development, coaching, and performance feedback for members of the GRA functional teams
  • As a people manager within the organization, may have financial accountabilities and human resource responsibilities for assigned staff.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment label boosts market penetration in Europe.
  • Partnership with Arbor Biotechnologies positions Vertex at the forefront of innovative treatments.
  • Recent investments indicate strong investor confidence in Vertex's growth potential.

What critics are saying

  • Recent layoffs suggest financial or strategic challenges impacting operational capabilities.
  • Discontinuation of diabetes asset indicates difficulty diversifying beyond cystic fibrosis.
  • Reliance on key products like ivacaftor makes Vertex vulnerable to market fluctuations.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's collaboration with Arbor Biotechnologies advances novel ex vivo engineered cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Pharmalive
Jun 11th, 2025
After axing diabetes asset, Vertex lays off 140 staff

After axing diabetes asset, Vertex lays off 140 staff.

PBN
Jun 10th, 2025
Vertex Pharmaceuticals to lay off 125 R.I. employees

PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.